207_Combined course Presentations

Regarding the HD12 trial:

Amongst the patients with bulk

 PFS in favor of RT arm @ 10 years (88.6% vs 83.5%), HR 1.47  OS marginally in favor of RT arm @ 10 years (93% vs 90.2%)

Amongst the patients with residual disease

 PFS in favor of RT arm @ 10 years (89.3% vs 83.4%)  OS in favor of RT arm @ 10 years (94.4% vs 88.4%)

No significant difference in terms of second cancer @ 10 years (9.7% vs 6.4%)